Clostridium

A large, polyphyletic genus of Gram-positive, obligate anaerobic, spore-forming bacteria encompassing both critical beneficial commensals and dangerous pathogens. Former Clostridium clusters IV and XIVa are now reclassified into ruminococcus-family Ruminococcaceae and lachnospiraceae respectively, though legacy nomenclature persists widely. Distinguishing beneficial from pathogenic species is essential when interpreting microbiome data.

Beneficial Species

Clusters IV and XIVa (Reclassified)

  • The dominant butyrate-producing communities in the healthy human colon, representing up to 40% of total fecal bacteria.
  • Depleted in multiple sclerosis: loss reduces SCFA production, impairs Treg differentiation and anti-inflammatory cytokine output [1].
  • Depleted across crohns disease, IBD broadly, colorectal cancer, and cardiovascular disease.
  • Induce colonic Tregs via butyrate-HDAC inhibition, a cornerstone of mucosal immune tolerance.

C. butyricum

  • Probiotic species used therapeutically in Japan and parts of Asia.
  • Produces butyrate via butyryl-CoA:acetate CoA-transferase pathway.
  • Protective against clostridioides difficile infection and necrotizing enterocolitis in premature infants.
  • Enhances gut barrier integrity through butyrate-mediated upregulation of tight junction proteins.

Pathogenic Species

C. perfringens

  • Produces at least 20 toxins including alpha-toxin (phospholipase C), beta-toxin, epsilon-toxin, and enterotoxin.
  • Causes gas gangrene, food poisoning, and necrotizing enteritis. iron-dependent virulence.

C. botulinum

  • Produces botulinum neurotoxin, the most potent biological toxin known.
  • The toxin is a zinc-metalloprotease that cleaves SNARE proteins at neuromuscular junctions.

C. difficile (now [[clostridioides-difficile]])

  • Reclassified to Clostridioides. Causes antibiotic-associated diarrhea and pseudomembranous colitis.
  • Opportunistic pathogen that blooms when beneficial Clostridium clusters are depleted by antibiotics.

Metal Dependencies

  • Iron: Ferredoxin iron-sulfur clusters are central to clostridial anaerobic metabolism and butyrate synthesis. Iron perturbation in the gut directly affects the metabolic output of beneficial species.
  • Cobalt: Some species require B12 (cobalamin) for key enzymatic reactions.
  • Zinc: Botulinum toxin is a Zn-metalloprotease; C. perfringens phospholipase C also requires metal cofactors.
  • Heavy metal stress cadmium, lead preferentially depletes beneficial clostridial clusters while sparing spore-forming pathogenic species, shifting the genus balance toward virulence.

Key Metabolites

  • Butyrate — primary SCFA from clusters IV/XIVa; HDAC inhibitor, colonocyte fuel, anti-inflammatory.
  • Secondary bile acids — 7-alpha-dehydroxylation by C. scindens and related species converts primary to secondary bile acids (DCA, LCA), influencing cardiovascular disease and CRC risk [2].
  • Indole derivatives — tryptophan metabolism by some Clostridium species produces AHR ligands with immune-modulatory activity.

Disease Associations

  • Clostridium sp. CAG:307 enriched in endometriosis [3].
  • CAG9 (Clostridium) negatively correlated with glycerophospholipids in CAD severity analysis [4].
  • NSAID-induced enteropathy disrupts clostridial communities, reducing protective SCFA output [5].

Connections

  • lachnospiraceae — former cluster XIVa; major butyrate-producing family co-depleted in disease
  • ruminococcus — former cluster IV members; co-depleted in IBD and MS
  • clostridioides difficile — opportunistic pathogen that blooms when beneficial clostridia are depleted
  • multiple sclerosis — cluster IV/XIVa depletion impairs Treg function
  • colorectal cancer — beneficial species depleted; bile acid metabolism affects CRC risk
  • iron — Fe-S clusters essential for anaerobic metabolism and butyrate production
  • zinc — botulinum toxin mechanism; metal cofactors in virulence factors
  • dysbiosis — loss of beneficial clusters is a universal dysbiosis signature
  • inflammation — butyrate loss removes HDAC-mediated anti-inflammatory brake
  • gut metal microbiome — metal stress shifts genus balance from beneficial to pathogenic species

References (5)

  1. Matteo Bronzini, Alessandro Maglione, Rachele Rosso et al. (2023). Feeding the gut microbiome: impact on multiple sclerosis. Frontiers in Immunology. doi:10.3389/fimmu.2023.1176016
  2. Paul M. Ryan, Catherine Stanton, Noel M. Caplice (2017). Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. Diabetology and Metabolic Syndrome. doi:10.1186/s13098-017-0299-9
  3. Perez-Prieto I, Vargas E, Salas-Espejo E et al. (2024). Gut microbiome in endometriosis: a cohort study on 1000 individuals. BMC Medicine. doi:10.1186/s12916-024-03503-y
  4. Honghong Liu, Xi Chen, Xiaomin Hu et al. (2019). Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. doi:10.1186/s40168-019-0683-9
  5. Xianglu Wang, Qiang Tang, Huiqin Hou et al. (2021). Gut Microbiota in NSAID Enteropathy: New Insights From Inside. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2021.679396

Related Articles